Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT596 + Rituximab for Relapse Prevention in NHL
NCT04555811Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT596 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma (HGBCL), sponsored by Masonic Cancer Center. Started Sep 2020; status: completed.
02
Drugs
FT596
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT04555811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555811.